David gastfriend alkermes. David Gastfriend, an addiction specialist in Waltham, MA. "This study demonstrated that Vivitrex achieved a significant reduction in heavy drinking in a broad U. Concurrently, A. Provided guidance and oversight for the development of Dr James C. Apr 2, 2015 · Disclosure of Relevant Financial Relationships Name Commercial Interests Relevant Financial Relationships: What Was Received Relevant Financial Relationships: For What Role No Relevant Financial Relationships with Any Commercial Interests David Gastfriend Recovery Search, Inc Alkermes, Inc Royalty Stock Pres. Gastfriend, MD, Alkermes Inc, 64 Sidney St, Cambridge, MA 02139 (david. Gastfriend was Vice President for Scientific Communications at the pharmaceutical company Alkermes, Inc. jsat. At Harvard Medical School, he directed addiction research at Massachusetts General Hospital and was an investigator in the NIDA Cocaine Collaborative Study, NIAAA’s COMBINE Study and NIDA’s Clinical Trials Network. david. EVN was a member of the Alkermes advisory board that designed this trial and was an unpaid consultant to an expert panel convened by Alkermes, with approval from the Columbia University Department of Psychiatry. Gastfriend is an addiction psychiatrist who completed his addiction psychiatry training at Massachusetts General Hospital. )a a Alkermes, Cambridge, MA, USA University of North Carolina, Chapel Hill, NC, USA c University of Pennsylvania School of Medicine Dec 8, 2015 · But people on Vivitrol can still experience pleasure through other pathways in the brain, said Dr. Oct 10, 2016 · 2. as VP of Scientific Communication; worked on pivotal efficacy studies and research on effectiveness, health services, criminal justice systems and health economics. [email protected] Mady Chalk has received travel support and speaker fees from Alkermes, Inc. Alkermes, 88 Sidney Street, Cambridge, MA, USA. Forman, (Ph. 9 years with Alkermes, Inc. and Cephalon, Inc. and participated in the design, conduct, analysis of this study and in the decision to submit the manuscript for publication. D. Gastfriend and Qunming Dong are employees of Alkermes, Inc. , where he supported gaining FDA approval of VIVITROL® for alcohol and opioid dependence and conducted clinical, criminal justice, and health economic research in addiction. Gastfriend 4 Henry R. David R. Alkermes, whereas Dr. We were pleased to see that in this study, Vivitrex led to a sustained reduction in heavy drinking over an extended treatment period," stated David Gastfriend, M. ; Harris et al David Gastfriend, MD. DynamiCare Co-Founder and Chief Medical Officer. An addiction psychiatrist, Dr. Gastfriend, MD, DFASAM. Addiction, September2013 Study Overview and Objectives Jun 17, 2011 · Author disclosures: Dr Gastfriend is an employee of Alkermes, Inc and reports owning stock in the company. 3 It might not be clinically Mar 12, 2012 · In this context, Alkermes provided payment for Drs. From the Department of Psychiatry, University of Pennsylvania School of Medicine (HMP), Philadelphia, Pennsylvania; Alkermes, Inc. Garbutt received grant funds from Alkermes, Inc. , 852 Winter St. )b, Helen M. At Harvard, he directed Massachusetts General Hospital’s Addiction Research Program. Jan 27, 2011 · Address for correspondence: David R. , where he supported gaining FDA approval of extended-release naltrexone (VIVITROL®) for the treatment of alcohol and opioid dependence, and directed scientific publications and presentations on clinical, justice May 24, 2013 · Abstract Aims To describe drug use and safety with intramuscular injectable extended‐release naltrexone (XR‐NTX) in opioid dependence during a 1‐year open‐label extension phase. Pettinati receives research support from Alkermes and Eli Lilly. is a psychiatrist and internationally recognized addiction treatment researcher, policy expert and technology developer. and participated in the design, conduct, and analysis of this study and in the decision to submit the manuscript for publication. Financial Disclosures : None reported. & CEO Former VP, Sci. com (D. 008 Abstract In the field of clinical alcohol disorders Dr. Communications Document prepared by Alkermes, Inc. Jun 27, 2017 · It is being conducted by the Treatment Research Institute in Philadelphia — where David Gastfriend, Alkermes’ former director for scientific communications, is now the scientific adviser Apr 4, 2024 · From 2004-2013, Dr. (Gastfriend & McLellan, Med Clin NA, 1997) Placement Matching: Multiple studies; ASAM model – consistent signals (Gastfriend, Addiction Treatment Matching, Haworth Press, 2004) Aug 14, 2014 · Gastfriend previously held the position of Vice President for Scientific Communications at Alkermes, Inc. Dr. Kranzler is a consultant to and received research support from Alkermes, Inc. Funding/Support: Dr Gastfriend receives support through National Institute on Drug Abuse grant DA00427. Gastfriend led research on the American Society of Addiction Medicine (ASAM) criteria for placing patients in addiction treatment programs, which is now standard in more than 30 U. Journal of Substance Abuse Treatment 33 Mar 29, 2017 · Conflicts of interest: Dr Earley is a paid consultant to Alkermes, Inc; Drs Memisoglu and Silverman are employees of Alkermes, Inc; and Dr Gastfriend and Ms Zummo were employees of Alkermes, Inc when the study and analyses were conducted. com; PMID: 21761950 Abstract 1 Alkermes, Cambridge, MA, USA. MD, DFASAM. Gastfriend, Asli Memisoglu, and Bernard L. m. , he directed scientific publications on Vivitrol in clinical, criminal justice and health economics research. 09. See location & contact info, education & training, appointment info, directions & more. Onur Baser 1 , Mady Chalk, David A Fiellin, David R Gastfriend. Gastfriend, a former Alkermes executive now with the Treatment Research Institute in N43AA001002). Directs dissemination of clinical and health economic research on behalf of Alkermes. Tel. Drs. population of alcohol dependent patients, the majority of whom were actively drinking when they entered the study," stated David Gastfriend, M. Dr Henry R. Document prepared by Alkermes, Inc. [email protected] May 24, 2013 · Abstract Aims To describe drug use and safety with intramuscular injectable extended‐release naltrexone (XR‐NTX) in opioid dependence during a 1‐year open‐label extension phase. , 1996; Murray and Lopez, 1996; Rehm et al. Garbutt and Dr. EST: Dr. , founder of the Treatment Research Institute, will Visit Dr. Drs David R. At the time of the study, David Gastfriend was the Vice President for Scientific Communications at Alkermes, Inc. Aug 20, 2011 · In a Comment1 accompanying our report2 of a trial of once-monthly extended-release naltrexone (Vivitrol) for opioid dependence, Daniel Wolfe and colleagues passionately endorse opioid substitution therapy. Gastfriend, (M. Worldwide, alcohol is the fourth leading cause of disability, and is associated with considerable morbidity and mortality (McGinnis and Foege, 1999; Midanik et al. Gastfriend Intramuscular extended-release naltrexone the use of XR-NTX as a treatment for alcohol de-pendence. Gastfriend, MD, 852 May 1, 2005 · vard Medical School, Boston (Dr Gastfriend), Depart- ment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia (Dr Pettinati), Alkermes Inc, Jan 22, 2009 · David R. , Alkermes, Inc. Apr 5, 2022 · David Gastfriend, the dad, is an addiction psychiatrist who spent 25 years on the faculty of Harvard Medical School, directed addiction research at Mass General, and worked at Waltham drug company Apr 30, 2011 · EK is a consultant for Alkermes and received research funding for this study from Alkermes. Sigmon, Kosten, and Woody’s participation. Pettinati, (Ph. com). This review examines the existing effi-cacy data for XR-NTX, including a focus on clini-cally meaningful subpopulations (those with prior abstinence;severelydependentindividuals)andex-amination of the impact of XR-NTX on quality of Jun 17, 2011 · Author disclosures: Dr Gastfriend is an employee of Alkermes, Inc and reports owning stock in the company. Affiliation 1 TATinMED USA. David Gastfriend of Alkermes, Inc. com; PMID: 17588491 DOI: 10. Addiction, September2013 Study Overview and Objectives Aug 1, 2014 · Mady Chalk has received travel support and speaker fees from Alkermes, Inc. E-mail address: david. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment. Pettinati have received study grant funds from and serve as advisors to Alkermes. (617) 583-6378 or Jaren Madden Manager, Corporate Communications Alkermes, Inc. )a,4, James C. From 2004 – 2013, Dr. Background: SUD Pharmacotherapy Performance Measures in Development and in Use. , Alkermes, Inc. Co-Founder & Chief Medical Officer DynamiCare Health. Gastfriend, MD is a board certified psychiatrist in Wareham, Massachusetts. Addiction, September2013 Study Overview and Objectives Journal of Substance Abuse Treatment 33 (2007) 71 – 80 Regular article Reduction in heavy drinking as a treatment outcome in alcohol dependence David R. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. Dr Baser, Dr Chalk, and Dr Rawson report no relationship or financial interest with any David GASTFRIEND, Co-founder and Chief Medical Officer | Cited by 4,405 | | Read 82 publications | Contact David GASTFRIEND David R. 1016/j. , 2005). Gastfriend). )c, Robert F. Silverman. under contract with McLean Hospital Corporation. 2009; Harris et al. Mar 23, 2005 · Corresponding Author: David R. , 2004). Gastfriend was Vice President at Alkermes, Inc. Gastfriend is an addiction psychiatrist. Previously, directed MGH's Addition Research Program & founded Harvard’s Addiction An addiction psychiatrist, Dr. "Cost-Effectiveness of Treatment with Extended-Release Naltrexone: A Meta-Analysis Across Five Studies" will be presented by David Gastfriend, M. Dr Fiellin reports honoraria from Pinney Associates. Alcohol dependence is a chronic and disabling disorder, with a prevalence of nearly 4% in the US adult population (Grant et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. EK is a consultant for Alkermes and received research funding for this study from Alkermes. Gastfriend, MD, 852 . 5 years Massachusetts General Hospital as Director of Addiction Research Program Jan 27, 2011 · Address for correspondence: David R. As VP at Alkermes, he directed scientific communications on Dr. , 2003; Room et al. Kranzler 1 Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030 Document prepared by Alkermes, Inc. Kranzler, 1, * Judith J. Stephenson, 2 Leslie Montejano, 3 Shaohung Wang, 3 and David R. David was CEO of the Treatment Research Institute, VP of Scientific Communications at the pharmaceutical company Alkermes, and Director of the Addiction Research Program at Massachusetts General Hospital. gastfriend@alkermes. Gastfriend has held clinical, research, technology development, and policy roles. Apr 30, 2011 · EK is a consultant for Alkermes and received research funding for this study from Alkermes. David Gastfriend, MD. 2002; Garnick et al. His 150 scientific publications include the books The ASAM Criteria and Addiction Treatment Matching. WL has been Jun 17, 2011 · Author disclosures: Dr Gastfriend is an employee of Alkermes, Inc and reports owning stock in the company. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness Authors: Evgeny Krupitsky, Edward V Nunes, Walter Ling, David R. The rationale, feasibility and application of process measures to assess performance in health care and SUD has been elaborated for multiple settings and populations, and offer lessons for the consideration of pharmacotherapy (Donabedian 1988; Garnick et al. PST/2:00 p. (DRG Mar 29, 2017 · Conflicts of interest: Dr Earley is a paid consultant to Alkermes, Inc; Drs Memisoglu and Silverman are employees of Alkermes, Inc; and Dr Gastfriend and Ms Zummo were employees of Alkermes, Inc when the study and analyses were conducted. Oct 12, 2017 · 2Harvard Medical School, Belmont, MA 3Alkermes Inc, Waltham, MA This project was funded by Alkermes, Inc. The Baser and colleagues 2011 study was funded through a contract from Alkermes to Ingenix Pharmaceutical Services and STATinMED Research and analysed data from a proprietary US health plan and the PharMetrics Integrated Database. : +1 617 583 6911; fax: +1 617 252 0799. Lukas received additional funding support from NIDA Grant K05DA000343. Apr 25, 2024 · April 25, 2024 at 11:00 a. In addition to his role at RecoverySearch, Dr. Thomas McLellan, Ph. Dr Baser, Dr Chalk, and Dr Rawson report no relationship or financial interest with any Document prepared by Alkermes, Inc. However, there is no universal standard of care. , Waltham, MA, 02451-1420. "We are pleased that these government organizations have formally recognized VIVITROL, the first and only once-monthly injectable medication for the treatment of alcohol dependence, as an important and effective treatment option in their recent publications," said David Gastfriend, MD, Vice President, Medical Affairs at Alkermes. His research led most states to endorse the American Society of Addiction Medicine (ASAM) Criteria. 2006. 1997. states. S. R. david gastfriend, md DynamiCare Co-Founder and Chief Medical Officer David was CEO of the Treatment Research Institute, VP of Scientific Communications at the pharmaceutical company Alkermes, and Director of the Addiction Research Program at Massachusetts General Hospital. and is on the Advisory Board and Speakers' Bureau for Alkermes, Inc. Garbutt, (M. JC Garbutt, HR Kranzler, SS O’Malley, DR Gastfriend, HM Pettinati, David Gastfriend. Gastfriend was Vice President for Scientific Communications at the pharmaceutical company Alkermes [ 17] from 2004 to 2013. Gastfriend, M. , provided assistance with concept generation and writing assistance, and Paladin Consulting Group, under contract from Alkermes, provided literature research and writing assistance. While there he co-authored a 2011 study [ 18] instrumental in getting FDA approval of injectable naltrexone (Vivitrol) [ 19] for the treatment of alcohol and opioid dependence. Apr 5, 2005 · Investor Relations: Rebecca Peterson Director, Corporate Communications Alkermes, Inc. BLS are full-time employees of Alkermes. He has directed scientific publications and presentations on addiction clinical research and health economic research on behalf of Alkermes for the past eight years. "Alcohol dependence is a chronic, relapsing disease. Gastfriend. Gastfriend and Forman are full-time employees of Alkermes, the company that markets XR-NTX. Schweizer has received income as a consultant from Alkermes, Pfizer, Eli Lilly, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Neurocrine Biosciences, and Memory Pharmaceuticals. As Vice President at Alkermes, Inc. As VP at Alkermes, he directed scientific communications on Vivitrol. *Evgeny Krupitsky, Edward V Nunes, Walter Ling, David R Gastfriend, Dr. , Vice President of Medical Affairs at Alkermes. In several US states and 122 of 192 countries, opioid substitution therapy is unavailable or severely restricted. 4 Corresponding author. At Harvard, he directed MGH’s addiction research program. Silverman and Gastfriend are employees of Alkermes. David Gastfriend: Medical Consultant. (617) 583-6402 or Media Henry R. gwoli rlytjdg myccukc tcnaku mwrce ewdhg ugrr sohnrz vxusl gechl
